Fenwick noted an increasing number of companies, particularly in the life sciences industry (e.g., pharmaceuticals, biotechnology, medical devices, biomedical technologies), that are flagging the potential implications of the US Supreme Court’s recent Loper Bright Enterprises decision (blogged here) in their risk factor disclosure.
Examples of recent Form 10-Q risk factor disclosures directly or indirectly referencing this decision and/or other relevant US Supreme Court administrative law decisions are included in this Bryan Cave memo.
Courtesy of Intelligize, this worksheet reflects risk factor disclosures in Form 10-K and 10-Q filings across industries over the past ~90 days that specifically reference the Loper Bright decision and/or the reversal of Chevron deference.
This post first appeared in the weekly Society Alert!